We recently published 17 Stocks Jim Cramer Talked About. Eli Lilly and Company (NYSE:LLY) is one of the stocks that Jim Cramer talked about. Pharmaceutical giant Eli Lilly and Company (NYSE:LLY)’s ...

Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’s top growth stock picks. On February 18, Eli Lilly and Company (NYSE:LLY) said using Taltz (ixekizumab) together with Zepbound (tirzepatide) ...

Eli Lilly (LLY) announced on Wednesday that a late-stage trial designed to test a combination regimen containing its weight loss therapy Zepbound and psoriasis therapy Taltz reached the main goals.

Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Nike (Symbol: NKE), where a total of 86,249 contracts have traded so far, representing ...

Eli Lilly (LLY) has announced a Phase 3 trial win for its targeted cancer therapy Retevmo (selpercatinib) in patients with a specific type of lung cancer who have previously undergone initial therapy ...

Eli Lilly (LLY) reported Q4 EPS of $7.54 versus $6.67 expected. Eli Lilly projected 2026 revenue of $80-83B. Eli Lilly’s Mounjaro revenue surged 110% to $7.4B in Q4. Zepbound revenue jumped 123% to $4 ...

Eli Lilly makes the best-performing GLP-1 drugs on the market today. The company faces intense competition and has a relatively short window of opportunity. Wall Street is massively excited by the ...

Eli Lilly has been busy building its drug pipeline for the future. The company currently sells the world's best-selling drug. It just bought Orna Therapeutics, an innovative drugmaker. Investing in ...

Eli Lilly LLY-1.01%decrease; red down pointing triangle received approval from the Food and Drug Administration for a label expansion of its weight-loss drug Zepbound, adding a new monthly delivery ...

Eli Lilly (NYSE: LLY) just delivered 45% revenue growth and guided toward $83 billion in 2026 sales. With blockbuster obesity drugs, multiple growth catalysts, and analysts targeting $1,500, this ...